Monocenter, Open-Label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volunteers.

Trial Profile

Monocenter, Open-Label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2013

At a glance

  • Drugs Ethinylestradiol/dienogest (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 28 Sep 2008 Trial identifier 91539 added as reported by CT.gov
    • 12 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top